Manufacturing innovation to drive down cell therapy costs
Trends in Biotechnology · 2023
DOI: 10.1016/j.tibtech.2023.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Biotechnology, 2023. Verfasst von Minsoo Khang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Boston Consulting Group, Boston, MA, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor T cells (CAR-T) have demonstrated their potential to revolutionize cancer treatment. However, manufacturing remains a challenge. Multiple manufacturing innovations [e.g., vector and gene engineering, process improvements, hardware innovation, digital innovation, and point-of-care (POC) manufacturing] have the potential to help realize the full potential of CAR-T therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boston Consulting Group, Boston, MA, USA.
- B Capital Group, San Francisco, CA, USA.
- Boston Consulting Group, Boston, MA, USA. Electronic address: topp.shana@bcg.com.
- Boston Consulting Group, Boston, MA, USA. Electronic address: wu.john@bcg.com.
Zitieren
APA
Khang, M., Suryaprakash, S., Kotrappa, M., Mulyasasmita, W., Topp, S., & Wu, J. (2023). Manufacturing innovation to drive down cell therapy costs. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2023.04.006
Vancouver
Khang M, Suryaprakash S, Kotrappa M, Mulyasasmita W, Topp S, Wu J. Manufacturing innovation to drive down cell therapy costs. Trends in Biotechnology. 2023. doi:10.1016/j.tibtech.2023.04.006
BibTeX
@article{Khang2023,
author = {Khang, Minsoo and Suryaprakash, Smruthi and Kotrappa, Megan and Mulyasasmita, Widya and Topp, Shana and Wu, John},
title = {Manufacturing innovation to drive down cell therapy costs},
journal = {Trends in Biotechnology},
year = {2023},
doi = {10.1016/j.tibtech.2023.04.006}
}
EUVIMED